MedTrace Logo

Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults

NCT03706261 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 145

Last updated 2025-08-01

Study results available
· View outcomes & findings →

Summary

The study employs tau positron emission tomography (PET) imaging in a well-characterized multi-racial/ethnic cohort to examine the extent to which tau pathology is associated with cognition, differences in tau pathology across racial/ethnic groups, and the relationship between MRI markers of small-vessel cerebrovascular disease and tau pathology. The study also investigates amyloid-dependent tau spreading.

Conditions

  • Alzheimer Disease

Interventions

DRUG

18F-MK-6240

Administration of 5 mCi of 18F-MK-6240 for tau PET.

DRUG

18F-Florbetaben

Administration of 8.1 mCi as a slow single intravenous bolus (6 sec/mL) in a total volume of up to 10 mL of 18F-Florbetaben for Aβ PET imaging.

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Adam Brickman

    lead OTHER

Principal Investigators

  • Adam M. Brickman, Ph.D. · Columbia University

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-03-22
Primary Completion
2023-07-14
Completion
2023-07-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03706261 on ClinicalTrials.gov